JIA | IgM RF+ polyarthritis | IgM RF- polyarthritis | Oligoarthritis | Systemic arthritis | Psoriatic arthritis | Enthesitis-related arthritis | |
---|---|---|---|---|---|---|---|
n=95 | n=16 | n=36 | n=24 | n=13 | n=3 | n=3 | |
Sex, no. females/males | 77/18 | 14/2 | 30/6 | 22/2 | 8/5 | 3/0 | 0/3 |
Age, median (IQ range) | 12 (5–16) | 14.5 (9.8-16) | 12 (5.3-15.5) | 10 (4.3-12) | 10.5 (4.8-14.3) | 17 (15–17)* | 16 (5–17)* |
Disease duration, median (IQ range) | 2 (0.5-6.5) | 0.5 (0.4-5.1) | 2.3 (0.6-6) | 2 (0.6-8.1) | 3.8 (1–9.5) | 4 (0–8)* | 2.5 (1–7)* |
Tender/swollen joint count, median (IQ range) | 8 (2–10) | 10 (8–13) | 8 (6–12) | 1 (1–2) | 9 (1–22) | 2 (1–8)* | 2 (1–2)* |
No. patients with joint damage (%) | 20 (20.8) | 5 (31.3) | 10 (27.8) | 1 (4.2) | 4 (30.8) | 0 (0.0) | 0 (0.0) |
CRP, median (IQ range) mg/dl | 0.7 (0.3-1.9) | 2.6 (0.8-13.3) | 0.80 (0.3-4.8) | 0.8 (0.3-5.5) | 4.9 (2.2-16.3) | 0.7 (0.33-2.1)* | 0.4 (0.3-2.7)* |
(% positive) | (36.8) | (50.0) | (33.3) | (25.0) | (29.2) | (33.3) | (33.3) |
ESR, median (IQ range) mm/hr | 16 (7–37) | 20 (8–31) | 14 (7–32) | 15 (7–31) | 30 (7–50) | 6 (6–32)* | 7 (2–7)* |
(% positive) | (50.5) | (68.8) | (44.4) | (45.8) | (69.2) | (33.3) | (0.0) |